This week's stories include study data on 2 RSV vaccines for seniors; an update on C diff therapies; looking at Ending the HIV Epidemic initiative; and a study on Paxlovid and Long COVID.
Monthly elebsiran plus tobevibart achieved undetectable HDV RNA with ALT normalization in 44% of patients at week 48 in the pivotal phase 3 ECLIPSE 1 trial.
Charles M. Walworth, MD, of Labcorp discusses a new hepatitis D reflex pathway, internal data showing 8.3% of HBsAg-positive patients screened for HDV, and lessons from hepatitis C reflex testing.
The Bundibugyo Ebola outbreak in the Democratic Republic of Congo has reached 11,145 confirmed cases and 5437 deaths, now the second-largest Ebola outbreak on record.
The Pan American Health Organization has reportedly revoked the US measles elimination status after more than 12 months of continuous transmission, as 2026 cases top 5,400, states report 10 deaths, and kindergarten MMR coverage has fallen to 92.4%.
The Peggy Lillis Foundation's CEO and Co-founder Christian Lillis discusses the organization's initiatives for C diff month, and offers a glimpse of the upcoming Scientific Symposium they are hosting next week.
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.